Aclaris Therapeutics to stop development of rheumatoid arthritis drug
Nov 13 (Reuters) - Aclaris Therapeutics ACRS.O on Monday said it will stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial. (Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Aclaris Therapeutics Q3 revenue beats analyst estimates
Brief: Aclaris Therapeutics Q3 Net Income USD -18.51 Million Vs. IBES Estimate USD -23.7 Million
Aclaris Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aclaris Therapeutics Q2 revenue beats analyst estimates